Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Leveraging global relationships in response to comparator drug discontinuation delivers study success
While globalisation and the rapid development of innovative new drugs are contributing to improved human health, it is also introducing additional challenges for sponsors to overcome.
Comparator sourcing is no exception. Take for example the field of oncology, which already makes up 25 per cent of the global late stage pipeline and where innovation in cancer drug development is predicted to continue to surge over the next five yearsi. With most investigational products studied against the existing standard of care, the demand for comparator products in this therapeutic area – as well as others - is forecast to rise dramaticallyii . Indeed, patterns are already beginning to emerge that indicate that timely availability of comparator products (or a lack there of) are posing a significant threat to clinical trials.
Download this case study to find out more.